QULIPTA

Trials studying QULIPTA

• phase4Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Studyrecruitingn=1,335
• phase3A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migrainerecruitingn=450
• phase3A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Yearsrecruitingn=420
• —Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migrainerecruitingn=3,000
• phase3Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migrainecompletedn=75
• phase3Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraineactive not recruitingn=1,300
• phase3Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migrainerecruitingn=430
• phase3A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migrainecompletedn=596